Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Correction: Tumour-infiltrating CD8+ lymphocytes and colorectal cancer recurrence by tumour and nodal stage.

Glaire MA, Domingo E, Sveen A, Bruun J, Nesbakken A, Nicholson G, Novelli M, Lawson K, Oukrif D, Kildal W, Danielsen HE, Kerr R, Kerr D, Tomlinson I, Lothe RA, Church DN.

Br J Cancer. 2019 Sep 23. doi: 10.1038/s41416-019-0590-7. [Epub ahead of print]

PMID:
31548598
2.

Tumour-infiltrating CD8+ lymphocytes and colorectal cancer recurrence by tumour and nodal stage.

Glaire MA, Domingo E, Sveen A, Bruun J, Nesbakken A, Nicholson G, Novelli M, Lawson K, Oukrif D, Kildal W, Danielsen HE, Kerr R, Kerr D, Tomlinson I, Lothe RA, Church DN.

Br J Cancer. 2019 Sep;121(6):474-482. doi: 10.1038/s41416-019-0540-4. Epub 2019 Aug 7. Erratum in: Br J Cancer. 2019 Sep 23;:.

3.

A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer.

Workel HH, Lubbers JM, Arnold R, Prins TM, van der Vlies P, de Lange K, Bosse T, van Gool IC, Eggink FA, Wouters MCA, Komdeur FL, van der Slikke EC, Creutzberg CL, Kol A, Plat A, Glaire M, Church DN, Nijman HW, de Bruyn M.

Cancer Immunol Res. 2019 May;7(5):784-796. doi: 10.1158/2326-6066.CIR-18-0517. Epub 2019 Mar 14.

PMID:
30872264
4.

Pattern Recognition Receptor Polymorphisms as Predictors of Oxaliplatin Benefit in Colorectal Cancer.

Gray V, Briggs S, Palles C, Jaeger E, Iveson T, Kerr R, Saunders MP, Paul J, Harkin A, McQueen J, Summers MG, Johnstone E, Wang H, Gatcombe L, Maughan TS, Kaplan R, Escott-Price V, Al-Tassan NA, Meyer BF, Wakil SM, Houlston RS, Cheadle JP, Tomlinson I, Church DN.

J Natl Cancer Inst. 2019 Jan 14. doi: 10.1093/jnci/djy215. [Epub ahead of print]

5.

Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas.

de Jonge MM, Auguste A, van Wijk LM, Schouten PC, Meijers M, Ter Haar NT, Smit VTHBM, Nout RA, Glaire MA, Church DN, Vrieling H, Job B, Boursin Y, de Kroon CD, Rouleau E, Leary A, Vreeswijk MPG, Bosse T.

Clin Cancer Res. 2019 Feb 1;25(3):1087-1097. doi: 10.1158/1078-0432.CCR-18-1443. Epub 2018 Nov 9.

PMID:
30413523
6.

Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series.

Domingo E, Camps C, Kaisaki PJ, Parsons MJ, Mouradov D, Pentony MM, Makino S, Palmieri M, Ward RL, Hawkins NJ, Gibbs P, Askautrud H, Oukrif D, Wang H, Wood J, Tomlinson E, Bark Y, Kaur K, Johnstone EC, Palles C, Church DN, Novelli M, Danielsen HE, Sherlock J, Kerr D, Kerr R, Sieber O, Taylor JC, Tomlinson I.

Lancet Gastroenterol Hepatol. 2018 Sep;3(9):635-643. doi: 10.1016/S2468-1253(18)30117-1. Epub 2018 Jul 2.

7.

Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response.

Temko D, Van Gool IC, Rayner E, Glaire M, Makino S, Brown M, Chegwidden L, Palles C, Depreeuw J, Beggs A, Stathopoulou C, Mason J, Baker AM, Williams M, Cerundolo V, Rei M, Taylor JC, Schuh A, Ahmed A, Amant F, Lambrechts D, Smit VT, Bosse T, Graham TA, Church DN, Tomlinson I.

J Pathol. 2018 Jul;245(3):283-296. doi: 10.1002/path.5081. Epub 2018 Apr 30.

8.

Adjuvant Treatment for POLE Proofreading Domain-Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues.

Van Gool IC, Rayner E, Osse EM, Nout RA, Creutzberg CL, Tomlinson IPM, Church DN, Smit VTHBM, de Wind N, Bosse T, Drost M.

Clin Cancer Res. 2018 Jul 1;24(13):3197-3203. doi: 10.1158/1078-0432.CCR-18-0266. Epub 2018 Mar 20.

9.

Changing Practice Evaluation-Stage 1 Seminoma: Outcomes With Adjuvant Treatment Versus Surveillance: Risk Factors for Recurrence and Optimizing Follow-up Protocols-Experience From a Supraregional Center.

Tyrrell HEJ, Church DN, Joseph J, Traill ZC, Sullivan ME, Tuthill MH, Verrill CL, Pintus EP, Dallas NL, Rogers PB, Redgwell J, Protheroe AS.

Clin Genitourin Cancer. 2018 Jun;16(3):240-244. doi: 10.1016/j.clgc.2017.12.001. Epub 2017 Dec 11.

PMID:
29336917
10.

CD103+ tumor-infiltrating lymphocytes are tumor-reactive intraepithelial CD8+ T cells associated with prognostic benefit and therapy response in cervical cancer.

Komdeur FL, Prins TM, van de Wall S, Plat A, Wisman GBA, Hollema H, Daemen T, Church DN, de Bruyn M, Nijman HW.

Oncoimmunology. 2017 Jul 24;6(9):e1338230. doi: 10.1080/2162402X.2017.1338230. eCollection 2017.

11.

Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.

Domingo E, Freeman-Mills L, Rayner E, Glaire M, Briggs S, Vermeulen L, Fessler E, Medema JP, Boot A, Morreau H, van Wezel T, Liefers GJ, Lothe RA, Danielsen SA, Sveen A, Nesbakken A, Zlobec I, Lugli A, Koelzer VH, Berger MD, Castellví-Bel S, Muñoz J; Epicolon consortium, de Bruyn M, Nijman HW, Novelli M, Lawson K, Oukrif D, Frangou E, Dutton P, Tejpar S, Delorenzi M, Kerr R, Kerr D, Tomlinson I, Church DN.

Lancet Gastroenterol Hepatol. 2016 Nov;1(3):207-216. doi: 10.1016/S2468-1253(16)30014-0. Epub 2016 Jul 20.

PMID:
28404093
12.

Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition.

Eggink FA, Van Gool IC, Leary A, Pollock PM, Crosbie EJ, Mileshkin L, Jordanova ES, Adam J, Freeman-Mills L, Church DN, Creutzberg CL, De Bruyn M, Nijman HW, Bosse T.

Oncoimmunology. 2016 Dec 9;6(2):e1264565. doi: 10.1080/2162402X.2016.1264565. eCollection 2017.

13.

Cancer predisposition syndromes: lessons for truly precision medicine.

Glaire MA, Brown M, Church DN, Tomlinson I.

J Pathol. 2017 Jan;241(2):226-235. doi: 10.1002/path.4842. Epub 2016 Nov 30. Review.

PMID:
27859368
14.

Practical guidance for mismatch repair-deficiency testing in endometrial cancer.

Stelloo E, Jansen AML, Osse EM, Nout RA, Creutzberg CL, Ruano D, Church DN, Morreau H, Smit VTHBM, van Wezel T, Bosse T.

Ann Oncol. 2017 Jan 1;28(1):96-102. doi: 10.1093/annonc/mdw542.

PMID:
27742654
15.

Value of Supraregional Multidisciplinary Review for the Contemporary Management of Testicular Tumors.

Purshouse K, Watson RA, Church DN, Richardson C, Crane G, Traill Z, Sullivan M, Roberts I, Browning L, Turner G, Parameshwaran V, Johnson J, Chitnis M, Protheroe A, Verrill C.

Clin Genitourin Cancer. 2017 Feb;15(1):152-156. doi: 10.1016/j.clgc.2016.05.005. Epub 2016 May 27.

PMID:
27324054
16.

POLE proofreading mutation, immune response and prognosis in endometrial cancer.

van Gool IC, Bosse T, Church DN.

Oncoimmunology. 2015 Aug 12;5(3):e1072675. eCollection 2016 Mar.

17.

A panoply of errors: polymerase proofreading domain mutations in cancer.

Rayner E, van Gool IC, Palles C, Kearsey SE, Bosse T, Tomlinson I, Church DN.

Nat Rev Cancer. 2016 Feb;16(2):71-81. doi: 10.1038/nrc.2015.12. Review.

PMID:
26822575
18.

Neoepitopes and CD3-Positive and CD8-Positive Cells in Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers.

van Gool IC, Bosse T, Church DN.

JAMA Oncol. 2016 Jan;2(1):141. doi: 10.1001/jamaoncol.2015.3900. No abstract available.

PMID:
26767552
19.

Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer.

Van Gool IC, Stelloo E, Nout RA, Nijman HW, Edmondson RJ, Church DN, MacKay HJ, Leary A, Powell ME, Mileshkin L, Creutzberg CL, Smit VT, Bosse T.

Mod Pathol. 2016 Feb;29(2):174-81. doi: 10.1038/modpathol.2015.147. Epub 2016 Jan 8.

20.

Vaccination of chemotherapy patients--effect of guideline implementation.

Toleman MS, Herbert K, McCarthy N, Church DN.

Support Care Cancer. 2016 May;24(5):2317-2321. doi: 10.1007/s00520-015-3037-6. Epub 2015 Nov 26.

PMID:
26610767
21.

Screening for Lynch syndrome and referral to clinical genetics by selective mismatch repair protein immunohistochemistry testing: an audit and cost analysis.

Colling R, Church DN, Carmichael J, Murphy L, East J, Risby P, Kerr R, Chetty R, Wang LM.

J Clin Pathol. 2015 Dec;68(12):1036-9. doi: 10.1136/jclinpath-2015-203083. Epub 2015 Jul 22.

PMID:
26201544
22.

POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer.

van Gool IC, Eggink FA, Freeman-Mills L, Stelloo E, Marchi E, de Bruyn M, Palles C, Nout RA, de Kroon CD, Osse EM, Klenerman P, Creutzberg CL, Tomlinson IP, Smit VT, Nijman HW, Bosse T, Church DN.

Clin Cancer Res. 2015 Jul 15;21(14):3347-3355. doi: 10.1158/1078-0432.CCR-15-0057. Epub 2015 Apr 15.

23.

Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative.

Stelloo E, Bosse T, Nout RA, MacKay HJ, Church DN, Nijman HW, Leary A, Edmondson RJ, Powell ME, Crosbie EJ, Kitchener HC, Mileshkin L, Pollock PM, Smit VT, Creutzberg CL.

Mod Pathol. 2015 Jun;28(6):836-44. doi: 10.1038/modpathol.2015.43. Epub 2015 Feb 27.

24.

Prognostic significance of POLE proofreading mutations in endometrial cancer.

Church DN, Stelloo E, Nout RA, Valtcheva N, Depreeuw J, ter Haar N, Noske A, Amant F, Tomlinson IP, Wild PJ, Lambrechts D, Jürgenliemk-Schulz IM, Jobsen JJ, Smit VT, Creutzberg CL, Bosse T.

J Natl Cancer Inst. 2014 Dec 12;107(1):402. doi: 10.1093/jnci/dju402. Print 2015 Jan.

25.

Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer.

Domingo E, Church DN, Sieber O, Ramamoorthy R, Yanagisawa Y, Johnstone E, Davidson B, Kerr DJ, Tomlinson IP, Midgley R.

J Clin Oncol. 2013 Dec 1;31(34):4297-305. doi: 10.1200/JCO.2013.50.0322. Epub 2013 Sep 23.

PMID:
24062397
26.

Stage II colon cancer.

Church DN, Midgley R, Kerr DJ.

Chin Clin Oncol. 2013 Jun;2(2):16. doi: 10.3978/j.issn.2304-3865.2013.03.03.

27.

DNA polymerase ε and δ exonuclease domain mutations in endometrial cancer.

Church DN, Briggs SE, Palles C, Domingo E, Kearsey SJ, Grimes JM, Gorman M, Martin L, Howarth KM, Hodgson SV; NSECG Collaborators, Kaur K, Taylor J, Tomlinson IP.

Hum Mol Genet. 2013 Jul 15;22(14):2820-8. doi: 10.1093/hmg/ddt131. Epub 2013 Mar 24.

28.

In reply: response to Marioni.

Church DN, Talbot DC.

Curr Oncol Rep. 2013 Feb;15(1):3. doi: 10.1007/s11912-012-0268-2. No abstract available.

PMID:
22932779
29.

Survivin in solid tumors: rationale for development of inhibitors.

Church DN, Talbot DC.

Curr Oncol Rep. 2012 Apr;14(2):120-8. doi: 10.1007/s11912-012-0215-2. Review.

PMID:
22234703
30.

Igf2 ligand dependency of Pten(+/-) developmental and tumour phenotypes in the mouse.

Church DN, Phillips BR, Stuckey DJ, Barnes DJ, Buffa FM, Manek S, Clarke K, Harris AL, Carter EJ, Hassan AB.

Oncogene. 2012 Aug 2;31(31):3635-46. doi: 10.1038/onc.2011.526. Epub 2011 Nov 28.

31.

Extended survival in women with brain metastases from HER2 overexpressing breast cancer.

Church DN, Modgil R, Guglani S, Bahl A, Hopkins K, Braybrooke JP, Blair P, Price CG.

Am J Clin Oncol. 2008 Jun;31(3):250-4. doi: 10.1097/COC.0b013e31815a43c4.

PMID:
18525303
32.
33.

Clinical review - small cell carcinoma of the bladder.

Church DN, Bahl A.

Cancer Treat Rev. 2006 Dec;32(8):588-93. Epub 2006 Sep 27. Review.

PMID:
17008012
34.

HER2-positive breast cancer brain metastases: multiple responses to systemic chemotherapy and trastuzumab--a case report.

Church DN, Bahl A, Jones A, Price CG.

J Neurooncol. 2006 Sep;79(3):289-92. Epub 2006 Jul 5.

PMID:
16821088
35.

Desmoplastic small round cell tumour: obstetric and gynecological presentations.

Church DN, Bailey J, Hughes J, Williams CJ.

Gynecol Oncol. 2006 Sep;102(3):583-6. Epub 2006 Apr 27.

PMID:
16643996

Supplemental Content

Loading ...
Support Center